Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766268 | 1.00 | RAB9A (0.52) | RAB9ANPC1MTNR1AMTNR1BKDM4E | |
| SCHEMBL4762869 | 0.99 | NPC1 (0.50) | RAB9ANPC1MTNR1AMTNR1BKDM4E | |
| SCHEMBL4770113 | 0.97 | KDM4E (0.49) | RAB9ANPC1MTNR1AMTNR1BKDM4E | |
| SCHEMBL5733487 | 0.94 | KDM4E (0.51) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5734369 | 0.88 | RAB9A (0.49) | RAB9ANPC1MTNR1AMTNR1BKDM4E | |
| SCHEMBL5733474 | 0.88 | NPC1 (0.48) | RAB9ANPC1MTNR1AMTNR1BKDM4E | |
| SCHEMBL5734004 | 0.85 | KDM4E (0.45) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5735991 | 0.84 | KDM4E (0.57) | RAB9ANPC1MTNR1AMTNR1BKDM4E | |
| SCHEMBL5735830 | 0.83 | KDM4E (0.49) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5737118 | 0.83 | MCL1 (0.50) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | claimed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| EP-1644364-A1 | TETRAZOL BENZOFURANCARBOXAMIDES WITH PI3K ACTIVITY AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050020631-A1 | 3-Substituted benzofurans as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2005-01-27 | — | — | US | claimed |
| WO-2004108709-A1 | TETRAZOL BENZOFURANCARBOXAMIDES WITH P13K AKTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | claimed |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | disclosed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1644364-A1 | TETRAZOL BENZOFURANCARBOXAMIDES WITH PI3K ACTIVITY AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050020631-A1 | 3-Substituted benzofurans as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004108709-A1 | TETRAZOL BENZOFURANCARBOXAMIDES WITH P13K AKTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020631-A1 | 3-Substituted benzofurans as therapeutic agents | CYP4F11, BPTF, F3 | RAB9A 3653/4885NPC1 865/4885MTNR1A 1171/4885 |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | PI4KB, PIK3CA, PI4KA | RAB9A 2159/4885NPC1 3415/4885MTNR1A 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.